<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Shinfield Pharmaceuticals</title>
	<atom:link href="https://www.shinfield-pharma.com/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.shinfield-pharma.com</link>
	<description>Shinfield Pharmaceuticals are comitted to providing unrivalled and affordable healthcare services using systematic evidence based on research and development</description>
	<lastBuildDate>Wed, 06 Jul 2022 08:23:47 +0000</lastBuildDate>
	<language>en-US</language>
		<sy:updatePeriod>hourly</sy:updatePeriod>
		<sy:updateFrequency>1</sy:updateFrequency>
	<generator>https://wordpress.org/?v=4.0.38</generator>
	<item>
		<title>England could lose 16,000 GPs</title>
		<link>https://www.shinfield-pharma.com/article-england-could-lose-16000-gps/</link>
		<comments>https://www.shinfield-pharma.com/article-england-could-lose-16000-gps/#comments</comments>
		<pubDate>Thu, 20 Nov 2014 15:11:28 +0000</pubDate>
		<dc:creator><![CDATA[admin]]></dc:creator>
				<category><![CDATA[Latest News]]></category>
		<category><![CDATA[News & Events]]></category>

		<guid isPermaLink="false">http://www.shinfield-pharma.com/?p=208</guid>
		<description><![CDATA[England could lose 16,000 GPs.]]></description>
				<content:encoded><![CDATA[<p><a href='http://www.pharmatimes.com/Article/13-07-16/England_could_lose_16_000_GPs.aspx'>England could lose 16,000 GPs</a>.</p>
]]></content:encoded>
			<wfw:commentRss>https://www.shinfield-pharma.com/article-england-could-lose-16000-gps/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA warns consumers about fraudulent Ebola treatment products</title>
		<link>https://www.shinfield-pharma.com/fda-warns-consumers-about-fraudulent-ebola-treatment-products/</link>
		<comments>https://www.shinfield-pharma.com/fda-warns-consumers-about-fraudulent-ebola-treatment-products/#comments</comments>
		<pubDate>Thu, 20 Nov 2014 14:41:18 +0000</pubDate>
		<dc:creator><![CDATA[admin]]></dc:creator>
				<category><![CDATA[Latest News]]></category>

		<guid isPermaLink="false">http://www.shinfield-pharma.com/?p=201</guid>
		<description><![CDATA[FDA warns consumers about fraudulent Ebola treatment products via FDA warns consumers about fraudulent Ebola treatment products. The U.S. Food [&#8230;]]]></description>
				<content:encoded><![CDATA[<p><a href="http://www.shinfield-pharma.com/wp-content/uploads/2014/11/fraudulent-drugs.jpg"><img src="http://www.shinfield-pharma.com/wp-content/uploads/2014/11/fraudulent-drugs-300x170.jpg" alt="fraudulent-drugs" width="300" height="170" class="alignnone size-medium wp-image-206" /></a><br />
FDA warns consumers about fraudulent Ebola treatment products</p>
<p>via <a href='http://www.worldpharmanews.com/fda/2860-fda-warns-consumers-about-fraudulent-ebola-treatment-products'>FDA warns consumers about fraudulent Ebola treatment products</a>.<br />
The U.S. Food and Drug Administration is advising consumers to be aware of products sold online claiming to prevent or treat the Ebola virus. Since the outbreak of the Ebola virus in West Africa, the FDA has seen and received consumer complaints about a variety of products claiming to either prevent the Ebola virus or treat the infection.</p>
<p>There are currently no FDA-approved vaccines or drugs to prevent or treat Ebola. Although there are experimental Ebola vaccines and treatments under development, these investigational products are in the early stages of product development, have not yet been fully tested for safety or effectiveness, and the supply is very limited. There are no approved vaccines, drugs, or investigational products specifically for Ebola available for purchase on the Internet. By law, dietary supplements cannot claim to prevent or cure disease.</p>
<p>Individuals promoting these unapproved and fraudulent products must take immediate action to correct or remove these claims or face potential FDA action.</p>
<p>It is important to note that according to the Centers for Disease Control and Prevention (CDC), Ebola does not pose a significant risk to the U.S. public. Unfortunately, during outbreak situations, fraudulent products that claim to prevent, treat, or cure a disease all too often appear on the market. The FDA monitors for these fraudulent products and false claims and takes appropriate action to protect consumers.</p>
<p>Ebola is the cause of a viral hemorrhagic fever disease. Symptoms include fever, headache, joint and muscle aches, weakness, diarrhea, vomiting, stomach pain, lack of appetite, and abnormal bleeding. Symptoms of the virus can appear anywhere from two to 21 days after exposure, but is most commonly seen on days eight to 10.</p>
<p>In the United States, Ebola is not a water-borne or food-borne illness and is not transmitted through the air. Ebola is spread through direct contact with the body fluids of an infected person, or with objects like needles that have been contaminated with the virus. People who do not show symptoms are not contagious.</p>
<p>Consumers who have seen these fraudulent products or false claims are encouraged to report them to the FDA. </p>
]]></content:encoded>
			<wfw:commentRss>https://www.shinfield-pharma.com/fda-warns-consumers-about-fraudulent-ebola-treatment-products/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Coffee may help effects of obesity</title>
		<link>https://www.shinfield-pharma.com/breaking-world-pharma-news/</link>
		<comments>https://www.shinfield-pharma.com/breaking-world-pharma-news/#comments</comments>
		<pubDate>Thu, 20 Nov 2014 14:24:01 +0000</pubDate>
		<dc:creator><![CDATA[admin]]></dc:creator>
				<category><![CDATA[Latest News]]></category>

		<guid isPermaLink="false">http://www.shinfield-pharma.com/?p=191</guid>
		<description><![CDATA[Chemical in coffee may help prevent obesity-related disease Friday, 14 November 2014 Researchers at the University of Georgia have discovered [&#8230;]]]></description>
				<content:encoded><![CDATA[<p>Chemical in coffee may help prevent obesity-related disease<br />
Friday, 14 November 2014</p>
<p>Researchers at the University of Georgia have discovered that a chemical compound commonly found in coffee may help prevent some of the damaging effects of obesity. In a paper published recently in Pharmaceutical Research, scientists found that chlorogenic acid, or CGA, significantly reduced insulin resistance and accumulation of fat in the livers of mice who were fed a high-fat diet.</p>
<p>&#8220;Previous studies have shown that coffee consumption may lower the risk for chronic diseases like Type 2 diabetes and cardiovascular disease,&#8221; said Yongjie Ma, a postdoctoral research associate in UGA&#8217;s College of Pharmacy and lead author of the paper. &#8220;Our study expands on this research by looking at the benefits associated with this specific compound, which is found in great abundance in coffee, but also in other fruits and vegetables like apples, pears, tomatoes and blueberries.&#8221;</p>
<p>During the past 20 years, there has been a dramatic increase in obesity in the United States. More than one-third of U.S. adults and approximately 17 percent of children are obese, according to the Centers for Disease Control and Prevention, and the annual medical cost of obesity is more than $147 billion.</p>
<p>Aside from weight gain, two common side effects of obesity are increased insulin resistance and the accumulation of fat in the liver. Left untreated, these disorders can lead to diabetes and poor liver function.</p>
<p>To test the therapeutic effects of CGA, researchers fed a group of mice a high-fat diet for 15 weeks while also injecting them with a CGA solution twice per week.</p>
<p>They found that CGA was not only effective in preventing weight gain, but it also helped maintain normal blood sugar levels and healthy liver composition.</p>
<p>&#8220;CGA is a powerful antioxidant that reduces inflammation,&#8221; said Ma, who works in the laboratory of professor Dexi Liu in the department of pharmaceutical and biomedical sciences. &#8220;A lot of evidence suggests that obesity-related diseases are caused by chronic inflammation, so if we can control that, we can hopefully offset some of the negative effects of excessive weight gain.&#8221;</p>
<p>But the authors are quick to point out that CGA is not a cure-all. Proper diet and regular exercise are still the best methods to reduce the risks associated with obesity.</p>
<p>The mice in this study received a high dose of CGA, much higher than what a human would absorb through regular coffee consumption or a diet rich in fruits and vegetables.</p>
<p>However, the researchers do believe that CGA may form the foundation of a treatment for those who need extra help. They plan to conduct more research to develop an improved CGA formulation specifically for human consumption.</p>
<p>&#8220;We&#8217;re not suggesting that people start drinking a lot of coffee to protect themselves from an unhealthy lifestyle,&#8221; said Ma, who is also a member of UGA&#8217;s Obesity Initiative. &#8220;But we do think that we might be able to create a useful therapeutic using CGA that will help those at risk for obesity-related disease as they make positive lifestyle changes.&#8221;</p>
<p>Ma Y, Gao M, Liu D.</p>
]]></content:encoded>
			<wfw:commentRss>https://www.shinfield-pharma.com/breaking-world-pharma-news/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Approves Conversion of Soliris® (eculizumab) Accelerated Approval in aHUS to Regular Approval for the Treatment of Patients with aHUS</title>
		<link>https://www.shinfield-pharma.com/fda-approves-conversion-of-soliris-eculizumab-accelerated-approval-in-ahus-to-regular-approval-for-the-treatment-of-patients-with-ahus/</link>
		<comments>https://www.shinfield-pharma.com/fda-approves-conversion-of-soliris-eculizumab-accelerated-approval-in-ahus-to-regular-approval-for-the-treatment-of-patients-with-ahus/#comments</comments>
		<pubDate>Thu, 28 Aug 2014 06:45:10 +0000</pubDate>
		<dc:creator><![CDATA[admin]]></dc:creator>
				<category><![CDATA[Latest News]]></category>
		<category><![CDATA[News & Events]]></category>

		<guid isPermaLink="false">http://shinfield-pharma.com/?p=108</guid>
		<description><![CDATA[Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque auctor aliquam lectus eget venenatis. Nam fermentum est quam, sit amet [&#8230;]]]></description>
				<content:encoded><![CDATA[<p> Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque auctor aliquam lectus eget venenatis. Nam fermentum est quam, sit amet porttitor quam blandit nec. </p>
<p>Morbi condimentum felis felis, in auctor sapien commodo ac. Donec eget felis arcu. Maecenas sit amet sapien vel eros commodo dictum. Aenean arcu orci, placerat ac consequat eget, facilisis et arcu. Nam eu tempus ligula, eu molestie nibh. Nulla luctus nulla et ligula ultricies dignissim.<br />
Etiam efficitur turpis id mattis tempor. Suspendisse ut dui sit amet sem porta gravida. Aliquam convallis metus et malesuada molestie. Nulla auctor dui arcu. Sed porttitor leo sed dui fringilla pharetra. Suspendisse lacinia orci et quam sagittis, sit amet maximus nisi accumsan. Cras fringilla justo eu nibh molestie euismod. Vivamus vestibulum, velit at pellentesque malesuada, odio odio dapibus arcu, quis porttitor massa massa a nisi. Praesent venenatis id nibh a commodo. Mauris venenatis luctus metus id tempor.</p>
<p> Pellentesque nisl tellus, dapibus in sapien tincidunt, lobortis faucibus mi. Quisque tempus fermentum erat, id volutpat justo accumsan at. Cras dignissim nunc in dui facilisis, vel posuere libero ornare. Pellentesque aliquam lectus ligula, ornare posuere lectus varius sed. Integer tincidunt, massa id scelerisque malesuada, nunc elit blandit nulla, mattis luctus tortor diam vitae tellus. Donec in egestas odio. Mauris auctor vitae orci at luctus. Donec justo eros, aliquam vitae consectetur vitae, varius a purus. Donec tincidunt mattis lorem. Quisque vel congue sem. Suspendisse eros nulla, mattis eu urna quis, tristique hendrerit purus.</p>
<p>Nam euismod laoreet sem non cursus. Sed a congue leo, in euismod diam. Pellentesque suscipit pellentesque elit id pulvinar. Duis placerat nunc justo, eget sodales mi lobortis congue. Duis quis est cursus, aliquet libero et, consequat augue. Vestibulum non sapien imperdiet, rhoncus purus id, euismod nisl. Nunc ut vestibulum libero. Sed tempus sollicitudin pulvinar. Duis vehicula quam turpis, ac tempus magna tristique vitae. Vivamus sed sapien porttitor, lacinia tortor ac, fringilla lorem.  </p>
<h6>Morbi condimentum felis felis</h6>
<p> Pellentesque nisl tellus, dapibus in sapien tincidunt, lobortis faucibus mi. Quisque tempus fermentum erat, id volutpat justo accumsan at. Cras dignissim nunc in dui facilisis, vel posuere libero ornare. Pellentesque aliquam lectus ligula, ornare posuere lectus varius sed. Integer tincidunt, massa id scelerisque malesuada, nunc elit blandit nulla, mattis luctus tortor diam vitae tellus. Donec in egestas odio. Mauris auctor vitae orci at luctus. Donec justo eros, aliquam vitae consectetur vitae, varius a purus. Donec tincidunt mattis lorem. Quisque vel congue sem. Suspendisse eros nulla, mattis eu urna quis, tristique hendrerit purus.</p>
<ul>
<li>Lobortis faucibus mi. Quisque tempus fermentum erat, id volutpat justo accumsan</li>
<li>Pellentesque nisl tellus, dapibus in sapien tincidunt, lobortis faucibus mi</li>
<li>Nam euismod laoreet sem non cursus</li>
<li>Donec tincidunt mattis lorem. Quisque vel congue</li>
<li>Vivamus vestibulum, velit at pellentesque malesuada, odio odio dapibus arcu</li>
<li>Suspendisse ut dui sit amet sem porta gravida</li>
</ul>
]]></content:encoded>
			<wfw:commentRss>https://www.shinfield-pharma.com/fda-approves-conversion-of-soliris-eculizumab-accelerated-approval-in-ahus-to-regular-approval-for-the-treatment-of-patients-with-ahus/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia</title>
		<link>https://www.shinfield-pharma.com/european-medicines-agency-accepts-marketing-authorization-application-for-asfotase-alfa-as-a-treatment-for-patients-with-hypophosphatasia/</link>
		<comments>https://www.shinfield-pharma.com/european-medicines-agency-accepts-marketing-authorization-application-for-asfotase-alfa-as-a-treatment-for-patients-with-hypophosphatasia/#comments</comments>
		<pubDate>Thu, 28 Aug 2014 06:44:08 +0000</pubDate>
		<dc:creator><![CDATA[admin]]></dc:creator>
				<category><![CDATA[Latest News]]></category>
		<category><![CDATA[News & Events]]></category>

		<guid isPermaLink="false">http://shinfield-pharma.com/?p=105</guid>
		<description><![CDATA[European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with HypophosphatasiaEuropean Medicines Agency Accepts [&#8230;]]]></description>
				<content:encoded><![CDATA[<p>European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with HypophosphatasiaEuropean Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with HypophosphatasiaEuropean Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with HypophosphatasiaEuropean Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with HypophosphatasiaEuropean Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia</p>
]]></content:encoded>
			<wfw:commentRss>https://www.shinfield-pharma.com/european-medicines-agency-accepts-marketing-authorization-application-for-asfotase-alfa-as-a-treatment-for-patients-with-hypophosphatasia/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)</title>
		<link>https://www.shinfield-pharma.com/european-commission-grants-orphan-drug-designation-to-soliris-eculizumab-for-the-treatment-of-patients-with-myasthenia-gravis-mg/</link>
		<comments>https://www.shinfield-pharma.com/european-commission-grants-orphan-drug-designation-to-soliris-eculizumab-for-the-treatment-of-patients-with-myasthenia-gravis-mg/#comments</comments>
		<pubDate>Thu, 28 Aug 2014 06:43:03 +0000</pubDate>
		<dc:creator><![CDATA[admin]]></dc:creator>
				<category><![CDATA[Latest News]]></category>
		<category><![CDATA[News & Events]]></category>

		<guid isPermaLink="false">http://shinfield-pharma.com/?p=102</guid>
		<description><![CDATA[European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)European Commission Grants [&#8230;]]]></description>
				<content:encoded><![CDATA[<p>European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)</p>
]]></content:encoded>
			<wfw:commentRss>https://www.shinfield-pharma.com/european-commission-grants-orphan-drug-designation-to-soliris-eculizumab-for-the-treatment-of-patients-with-myasthenia-gravis-mg/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
